Artikelen door HollandBIO

, ,

Europa pleit voor sterkere samenwerking op vaccineerbare aandoeningen

De Europese Commissie (EC) publiceert een voorstel, een zogenaamde Council Recommendation, om samenwerking rond vaccineerbare aandoeningen te versterken. Dit voorstel volgt kort op de oproep van het Europees Parlement voor een hogere vaccinatiegraad. EU-wijde actie is hard nodig, vindt ook de EC: “omdat zwakte van één land bij vaccineren, de gezondheid en veiligheid van alle burgers […]

CHMP Backs Expanded Use For Amgen’s Prolia To Patients With Glucocorticoid-Induced Osteoporosis

Amgen announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the marketing authorization of Prolia for the treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture. “Today’s positive opinion by the CHMP […]

pLADD Therapy Found to Induce Both Innate and Adaptive Immunity

Aduro Biotech presented preliminary observations from a case study of a patient with metastatic colorectal cancer treated in Aduro’s ongoing Phase 1 study of its personalized neoantigen-based immunotherapy (pLADD). This Phase 1 proof-of-concept study is designed to evaluate the safety and tolerability of pLADD immunotherapy in adults with metastatic colorectal cancer that is microsatellite stable […]

KH176 published in Scientific Reports

Khondrion, a leading clinical-stage pharmaceutical company focusing on small molecule therapeutics for mitochondrial diseases, announced the publication of a scientific article reporting on the development and unique mode of action of KH176, a clinical-stage drug candidate for the treatment of mitochondrial diseases. The work was carried out by the Khondrion R&D team in collaboration with […]

Shire and Takeda come to terms with a $64B deal

We have a deal—a preliminary one, at least. Late Tuesday, after a fifth buyout offer from Takeda, Shire said the Japanese drugmaker had finally landed on a proposal worth recommending to shareholders. It’s a cash-and-stock bid now worth $64 billion or so, about $4 billion more than its first offer. The deal still has to […]

MDxHealth: SelectMDx Included in Dutch DRG Reimbursement System

MDxHealth SA, a world leader in molecular diagnostics for urological cancers, announced the inclusion of SelectMDx for Prostate Cancer, its non-invasive ‘liquid biopsy’ test that helps to identify patients at increased risk of having aggressive prostate cancer, in the Dutch Diagnosis Related Groups (DRG) reimbursement system. The DRG reimbursement system was introduced in the Netherlands […]

Biogen and Ionis Expand Strategic Collaboration

Biogen and Ionis Pharmaceuticals announced that they have expanded their strategic collaboration through a new ten-year collaboration agreement to develop novel antisense drug candidates for a broad range of neurological diseases. This collaboration capitalizes on Biogen’s expertise in neuroscience research and drug development and Ionis’ leadership in RNA targeted therapies with the goal of developing […]

,

Big Data, Big Produce

In the last few decades, with the introduction of GMOs, the agricultural industry was turned upside down. Major consolidations between companies took place, while sustainability and big data have become ever more important. BioVox had a conversation on the most important trends within the agri-biotech sector with Johan Cardoen, Managing Director of VIB, and with […]

, ,

Adviesrapport Sneller, Beter en Goedkoper slaat de plank mis

Vandaag publiceerde de Raad voor Volksgezondheid en Samenleving (RVS) haar adviesrapport “Ontwikkeling nieuwe geneesmiddelen: Beter, sneller, goedkoper”. HollandBIO heeft reikhalzend uitgekeken naar het rapport. In de totaal gepolariseerde discussie rondom geneesmiddelenprijzen, legde de adviesvraag die ten grondslag aan het rapport lag namelijk de vinger op de zere plek. Want hoewel biotech haar belofte waarmaakt en […]